Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

A legfontosabb adatok

Ki végzi
Guangdong Hengrui Pharmaceutical Co., Ltd
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
114 fő vett részt
Kezdés
2023. szept. 4.
Befejezés
2026. jan. 21.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • SHR-1905 Injection
  • SHR-1905 Placebo Injection
A regiszteradat frissítve
2026. július 22.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • Weight ≥40kg
  • Diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP)
  • Bilateral nasal polyps at screening and baseline, total NPS ≥5, ≥2 points for each nostril
  • NCS ≥2 at screening and baseline
  • SNOT-22≥20 at screening period and baseline
  • Recorded persistent NP symptoms for over 4 weeks prior to screening
  • Subjects received standard therapy with intranasal corticosteroids (INCS) and remained stable during the 4 weeks prior to randomization
  • NP surgery in the past and/or ACERS treated with SCS occurred within 2 years before randomization (or with contraindications/ intolerances)

Ki nem vehet részt

  • Concomitant with immunodeficiency
  • Concomitant with contraindications or not suitable for nasal endoscopy
  • Infection within 2 weeks prior to screening to randomization that is clinically significant and/or should be treated with systemic antibiotics
  • Uncontrolled epistaxis within 4 weeks prior to randomization
  • Major surgery performed within 3 months prior to randomization, or surgery planned during the study, or treatments that may affect evaluations according to investigators
  • Parasitic infection within 6 months before randomization
  • Sinus or intranasal surgery (except for diagnostic biopsy) within 6 months prior to randomization, or changes in the nasal walls caused by sinus or intranasal surgery that made NPS evaluation impossible
  • Concomitant with active hepatitis B, positive hepatitis C virus antibodies, positive human immunodeficiency virus antibodies, or positive treponema pallidum antibodies
  • Transfusion of blood products or immunoglobulin within 4 weeks prior to randomization
  • SCS or additional INCS use within 4 weeks before randomization, or planned use during treatment period
  • Regular use of decongestants (local or systemic) within 4 weeks before randomization, except for during the endoscopic procedure
  • Adnimistration of live vaccine or viral vector vaccine within 4 weeks before randomization
  • Allergen immunotherapy within 8 weeks before randomization
  • Substance abuse, drug abuse, and/or excessive alcohol consumption within 1 year prior to randomization
  • Uncontrolled hypertension
  • Uncontrolled diabetes
  • Malignancies diagnosed within 5 years before randomization (except those with a low risk of metastasis or death)
  • Abnormalities of laboratory tests at screening or baseline
  • Prolonged QTc interval (>450ms for male and >470ms for female) or other clinically significant abnormal results of ECG at screening or baseline that may cause significant safety risks to subjects
  • Any comorbidities that may affect the efficacy evaluation of nasal polyps
  • Any comorbidities except for asthma that may affect blood EOS levels
  • FEV1 before the use of bronchodilator (pre-BD) was less than 50% at screening
  • Smoking history ≥10 pack-years, smoking at screening, or smoking cessation less than 6 months at screening
  • Pregnancy (including positive pregnancy test at screening or baseline), lactation, or pregnancy plan during study period

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to explore the reasonable dosage of SHR-1905 injection for CRSwNP.

A vizsgálat 4 csoportja

  • Treatment group A: SHR-1905 Injection(dose 1)A vizsgált kezelés

    Kezelés: SHR-1905 Injection

  • Treatment group B: SHR-1905 Injection(dose 2)A vizsgált kezelés

    Kezelés: SHR-1905 Injection

  • Treatment group C: SHR-1905 Injection(dose 3)A vizsgált kezelés

    Kezelés: SHR-1905 Injection

  • Placebo GroupPlacebo, összehasonlításként

    Kezelés: SHR-1905 Placebo Injection

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Efficacy and Safety Study of SHR-1905 in Patiens With Chronic Rhinosinusitis With Nasal Polyps
A regiszteradat frissítve
2026. július 22.